Data completeness
2/8 — Basic
MEPROBAMATE (meprobamate) by Bausch + Lomb is clinical pharmacology meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system. Approved for anxiety disorders, for the short-term relief of the symptoms of anxiety, anxiety and 1 more indications.
Drug data last refreshed 2h ago · AI intelligence enriched 3mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Meprobamate is an oral tablet carbamate derivative indicated for short-term relief of anxiety symptoms and anxiety disorders. It works by exerting effects at multiple sites in the central nervous system, including the thalamus and limbic system.
Pre-Launch
Pre-launch stage indicates early commercial team building; limited current spending data suggests market opportunity under evaluation.
Mechanism of Action
CLINICAL PHARMACOLOGY Meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system.
Worked on MEPROBAMATE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.